BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 27775694)

  • 21. [Breakthroughs in FLT3-mutated acute myeloid leukemia treatments].
    Najima Y
    Rinsho Ketsueki; 2023; 64(9):932-941. PubMed ID: 37793868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation.
    Schiller GJ; Tuttle P; Desai P
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):982-990. PubMed ID: 26785334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FLT3 inhibitors in acute myeloid leukemia.
    Wu M; Li C; Zhu X
    J Hematol Oncol; 2018 Dec; 11(1):133. PubMed ID: 30514344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of FLT3 inhibitors in acute myeloid leukemia.
    Zhao JC; Agarwal S; Ahmad H; Amin K; Bewersdorf JP; Zeidan AM
    Blood Rev; 2022 Mar; 52():100905. PubMed ID: 34774343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sorafenib as a Salvage Therapy in FLT3-ITD Negative Relapse/ Refractory Acute Myeloid Leukemia.
    Yang N; Gu Z; Liu Z; Huang W; Wang S; Wang L; Gao C
    Anticancer Agents Med Chem; 2018; 18(10):1489-1494. PubMed ID: 29521250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What FLT3 inhibitor holds the greatest promise?
    Stone RM
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):401-404. PubMed ID: 30466756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.
    Hogan FL; Williams V; Knapper S
    Curr Cancer Drug Targets; 2020; 20(7):513-531. PubMed ID: 32418523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
    Stansfield LC; Pollyea DA
    Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.
    Scholl S; Fleischmann M; Schnetzke U; Heidel FH
    Cells; 2020 Nov; 9(11):. PubMed ID: 33212779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maintenance therapy for
    Burchert A
    Haematologica; 2021 Mar; 106(3):664-670. PubMed ID: 33472354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FLT3-targeted treatment for acute myeloid leukemia.
    Arai Y; Chi S; Minami Y; Yanada M
    Int J Hematol; 2022 Sep; 116(3):351-363. PubMed ID: 35532877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
    Knapper S; Russell N; Gilkes A; Hills RK; Gale RE; Cavenagh JD; Jones G; Kjeldsen L; Grunwald MR; Thomas I; Konig H; Levis MJ; Burnett AK
    Blood; 2017 Mar; 129(9):1143-1154. PubMed ID: 27872058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.
    Metzelder S; Wang Y; Wollmer E; Wanzel M; Teichler S; Chaturvedi A; Eilers M; Enghofer E; Neubauer A; Burchert A
    Blood; 2009 Jun; 113(26):6567-71. PubMed ID: 19389879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Which FLT3 Inhibitor for Treatment of AML?
    Senapati J; Kadia TM
    Curr Treat Options Oncol; 2022 Mar; 23(3):359-380. PubMed ID: 35258791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation.
    Kida M; Kuroda Y; Kido M; Chishaki R; Kuraoka K; Ito T
    Int J Hematol; 2020 Aug; 112(2):243-248. PubMed ID: 32170661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.
    Larrosa-Garcia M; Baer MR
    Mol Cancer Ther; 2017 Jun; 16(6):991-1001. PubMed ID: 28576946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
    Sasaki K; Kantarjian HM; Kadia T; Patel K; Loghavi S; Garcia-Manero G; Jabbour EJ; DiNardo C; Pemmaraju N; Daver N; Dalle IA; Short N; Yilmaz M; Bose P; Naqvi K; Pierce S; Yalniz F; Cortes JE; Ravandi F
    Cancer; 2019 Nov; 125(21):3755-3766. PubMed ID: 31310323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.